Equities Analysts Set Expectations for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Chardan Capital increased their FY2025 earnings estimates for shares of Solid Biosciences in a note issued to investors on Wednesday, February 19th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($1.82) for the year, up from their previous estimate of ($2.03). Chardan Capital has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Several other equities analysts have also recently weighed in on SLDB. Citizens Jmp raised shares of Solid Biosciences to a “strong-buy” rating in a research note on Tuesday, December 10th. JMP Securities assumed coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 target price for the company. Wedbush assumed coverage on shares of Solid Biosciences in a research note on Friday, December 13th. They issued an “outperform” rating and a $16.00 target price for the company. Truist Financial assumed coverage on shares of Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 target price for the company. Finally, JPMorgan Chase & Co. decreased their target price on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Nine research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Solid Biosciences currently has a consensus rating of “Buy” and an average target price of $15.40.

Solid Biosciences Stock Down 3.7 %

NASDAQ SLDB opened at $5.78 on Monday. Solid Biosciences has a 12-month low of $2.88 and a 12-month high of $15.05. The company has a market capitalization of $234.55 million, a PE ratio of -1.90 and a beta of 2.01. The firm’s 50 day moving average is $3.83 and its 200-day moving average is $5.74.

Insider Activity

In related news, COO David T. Howton sold 5,072 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $28,403.20. Following the completion of the transaction, the chief operating officer now owns 15,663 shares of the company’s stock, valued at $87,712.80. The trade was a 24.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jessie Hanrahan sold 4,610 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the transaction, the insider now directly owns 14,235 shares of the company’s stock, valued at approximately $79,716. This trade represents a 24.46 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,069 shares of company stock valued at $137,301. 13.63% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its holdings in shares of Solid Biosciences by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock worth $53,000 after acquiring an additional 2,986 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Solid Biosciences by 10.5% in the fourth quarter. Rhumbline Advisers now owns 43,677 shares of the company’s stock worth $175,000 after acquiring an additional 4,161 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Solid Biosciences by 4.0% in the fourth quarter. Wellington Management Group LLP now owns 124,551 shares of the company’s stock worth $498,000 after acquiring an additional 4,747 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Solid Biosciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 509,802 shares of the company’s stock worth $2,040,000 after acquiring an additional 4,932 shares during the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Solid Biosciences by 12.3% in the fourth quarter. American Century Companies Inc. now owns 46,857 shares of the company’s stock worth $187,000 after acquiring an additional 5,126 shares during the last quarter. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.